Loading…
Loading…
Pretty impressive margin print here. It looks like, volumes were slightly above the high end of your guidance. But the leverage was pretty impressive
CAM was stand out for us. On the instrument side, LCMS, GC, double digits was standout
How are you thinking about the tariff assumptions, right? Are you assuming now a global minimum of 15%?
Can you just talk about what drives the back half step up comps to get tougher?
How did orders in a backlog grow? I'm curious. I know last quarter you were speaking about stimulus, China-related stimulus
Could you just quantify what is tariff versus FX dynamics on gross margins?
Did TQ benefit from from timing element here on on instrument side? The the sort of another related actually, that top line question is, you mentioned tariff rate. When when you say pricing benefit...
is that is that a reasonable framework on how we think about Agilent? Or are there any anything that's unique?
I think you had a restructuring charge, which wasn't there in prior quarters. Is this some new cost actions that hasn't been initiated?
Why is it slowing down to low singles? I think you said in 3Q. And when you apply that to overall company, right, I think it's stepping down by 250 basis points
is that being driven by stimulus or perhaps timing of the Chinese New Year? Maybe talk about the book-to-bill trends and what is that signaling?
what is the average age of the fleet? And when you do that math, what is incremental of that few hundred million versus a normal replacement cycle?
When you look at the first half versus second half, it does assume a back half step up. We're just curious. Is that being driven by end markets normalizing?
Is the guide assuming free cash flow down above it, there's a timing element and on the margin sort of similar cadence question, what is Q1 assuming
talk about your plans for sustaining strong growth of Cologuard. Is there an international angle here for Cologuard?
how durable is this double-digit growth in a category that's, you know, a pacemaker, low single-digit growth category
where are we from a penetration standpoint? What innings are we in?
What percentage of your installed base has been updated or convert to a -- where are we in the conversion cycle
What drives the back half acceleration rate when we look at Q1 starting point of 7%
your gross margins are still below pre-pandemic levels. So, I'm curious, when you look at the margins, how sustainable are these trends
excluding the comps, you guys said up low singles
Have you communicated this to customers? What have you told customers? I understand the guidance assumption, but I am curious, are customers willing to wait for a year for Novum to resolve?
You mentioned the operating model change. Curious on what has changed from prior model. How is this model better?
What is the issue, Andrew, that you've been able to identify, has Baxter been in touch with the FDA? When was the last communication? What has the FDA asked you or asked Baxter from a remediation p...
Q4, I just want to clarify, is the implied injectables something like down mid-teens on the pharma side? What drives that? And I think guide implies operating margin declines
Is it possible for you to give us a bridge, right? I think the fiscal '24 jump off of 16.5%. I know we have a number of moving parts between TSA, MSA, stranded costs
IV fluids are off allocation. Like why are hospitals still conserving fluids? And this Novum, I think the FDA letter noted 2 deaths. Historically, when we've had recalls, like sometimes it's taking...
If you look at second quarter, 1% to 2% for core Baxter. That's a 350 basis point decel at the midpoint from Q1 levels
Can you just remind us for context, like what's been share gains over the past few quarters? Has it accelerated?
Can you quantify what the headwind from Helene was in the quarter? And what drove the hurricane impact? It looks like pumps was very strong
Joel, maybe my first question on TSA and margins here. I know the optics, these are apples-to-oranges comparison rate, but the year on year, it does look margins were up 250 basis points
What was underlying excluding the onetimer headwinds, right, which segments did it impact on the bottom line
The 125 basis points of headwinds on pharma, biosciences in China, it looks like you're assuming essentially those 3 segments are flattish for the year
How you're funding this $2 billion buyback? Are you going to raise any debt? Why now?
Q4 is down sequentially, right? Is that the incremental tariff headwind from Q3 to Q4? And how should we think of fiscal '26
assuming the trial is a success, how should we think of adoption? And any update on U.S. FDA submission for TAVR?
What percentage of PFA procedures do you think are associated with mapping?
Maybe just talk about sequential margins just given Q1 was such a good execution from a margin standpoint?
maybe just walk us through on this strategic rationale. I think you guys mentioned call point synergies
your guide implies for Q4 double digits. So maybe talk about what changes sequentially from 3Q to 4Q
how are you thinking of M&A versus share repurchases, right, when you look at assets available in the deal pipeline
Was there any pull forward either in academic channels or biopharma channels
Implied growth of Q4 should accelerate to, you know, high singles, maybe 8 to 9%
What is Danaher's total exposure to pharma, pharma overall, including bioprocessing
The $350 million of that gross headwinds, is that a full year impact or a partial year impact
How much of that is being contemplated in Q1 and rest of the year? And can you just remind us on - of your M&A criteria
Was there anything one-off in Q1, maybe which is different versus the rest of the year? I think you mentioned, Pall
Can you just maybe express your bullishness on PROGRESS and how are you handling crossovers?
how you're thinking about share count here for second quarter and whether there was any weather impact
On Sabre, you called out a distributor impact in Q4. Could you quantify what the impact is? Are those sales coming back in Q1
What is, I guess, a great way to think about moderate AS? You know, when these patients are untreated, right, do they look like, low-risk TAVR patients
why isn't this performance a reflection of asymptomatic approval? I'm curious why you think the strength wouldn't sustain
there was a litigation charge. And it was non-GAAP, could you just remind us on what the charge was
Can you just walk us through what the implied back half gross margins? And I think the EPS guidance for 3Q in place, maybe a 25-ish kind of operating margins
You said double-digit revenues and EPS for 2016. Do you expect operating leverage for 2026
Japan was a little light. Maybe talk about trends within Japan
Are we expecting to offset, you know, that increment $0.10 to $0.15 of headwinds completely or should we be perhaps looking at the bottom half
given some of those items won't repeat, why shouldn't Q1 be better? Is there any one-offs outside of the extra day
I think there is a CED criteria. And when I look at the physician criteria, there is a cross-pollination collaboration between a variety of physicians
Talk about the $250 million number that you quoted. What does it assume? Is it assuming current inflation trends?
Back half does imply a step up. And when I look at your order growth and book-to-bill, it looks like your capital book-to-bill was well north of 1.1
What is fiscal 'twenty-six assuming for Flurcato? And you I know you mentioned China declines
I saw you guys signed a distribution agreement with CDL on your pharma diagnostics side for [ Flyrcado ]
capital book-to-bill, if you will, last 7 quarters, you've ranged it around 1.12. And I know fiscal '25, some of the revenue recognition was impacted
can you talk about capital environment across different regions, U.S., Europe and whether China has bottomed
any of these actions or things that you would call as causing regret if rates were to change, come down
free cash, it was lowered by maybe $0.5 billion. Is that all cash impact
what portion of that is U.S. to China versus China to U.S.? I think there was some talks maybe of exemptions from China
Q1, I think I heard you say flat margins. Is there anything one-off in Q1
Why is 2.5% to 3.5% like ex-China the right number, when Q4 -- we exited Q4 at 4% organic
Was there any timing element, I think you're annualizing at $80 million. If this thing can grow like strong double digits, right, this -- it could be a sizable organic contributor.
The -- are we excluding -- is COVID a headwind, Steve? Are we backing that out when we say mid-singles.
is the organic for the segment assuming down mid-singles?
Q1 was impacted by flu shortage, right? Shouldn't that go away and numbers improve
Are you seeing something now? Or is this more of a modeling assumption?
how do you make the bridge to the LRP of 57. Is skeletal still a headwind here in fiscal '25
we're looking at exit rates of 6% organic, right? And let's assume next year is north of 6%. The extra week is almost 2 points of growth. So are we looking at base organic excluding extra week some...
How should we monitor the progress? Are there any goalposts that we can look forward to in tracking the launch curves for RDN and Altaviva?
do you feel like we have enough mappers now? And if is supply in a place enough where you can hit the $2 billion
Why is earnings growth back-end loaded? Is this a mix impact on margins? I think Q4 gross margins came in below. Was there a product mix issue?
what gives you the confidence this is not a share loss? And I think related to that P&L management, right, this gross margin stood out. Any one-timers in gross margins?
the revenue per case on Affera is that 3x versus cryo?
You mentioned flattish growth in the quarter due to some disruption, what was the issue? When was it resolved? What gives us the confidence of strong double-digit growth in third quarter
what was the issue in labs, and was it all tied to Middle East?
is that assuming academic and government improves?
looks like maybe half to be -- came from below the line, right, between interest expense and higher pension income
You guys did 4% organic in Q4. I think your Q1 is implying 2% organic, correct me if I'm wrong. What causes that 4% to 2% step down
Your tariff headwinds should abate quite meaningfully, but should we see a more -- a little bit more robust margin expansion
When I look at your back half of '25, you're averaging 4.5%. So that 4% for '26 seems a step down from back half. What changes in how you think of price versus volume
should we think of Mettler's ability to fully offset that? And related to that fiscal '26, I think some of your peers have made some comments on tax rates
You did bring up services, some timing issues. Are those coming back in the back half
is the guide assuming you know, post the ninety-day pause for rates to tariff rates to creep back up, like, what is the guide assuming on tariffs
Q1 ex the shipping delays, you guys up 3% low singles. Q2, zero to one, what drives that step down in revenues
if you look at the Q4 performance here, headline 12%, excluding the shipping comp, the underlying is 6%, Wouldn't that imply like if that's your exit rate
what is your competitive landscape in China? Do you have local competition? And then how should we think about potential risk related to China
when you look at the annual guide, pro forma 2 to 4 implies I think a step down to 3% for the remainder of the year. Why
is the organic raise, is that all driven by removal of China Immunodiagnostics or did base go up?
How are you thinking about life science versus diagnostics relative to that two to three corporate?
how you're thinking about deal size. I know you mentioned, you know, returns metrics have to have to, you know, clear the hurdles. What is the potential for a merger of equals?
Can you elaborate that on is that, like, pharma? Is that academic and government customer base? Is that showing up in reagents or instruments?
should that 2% to 3% organic with 28% op margins translate to high singles EPS for '26?
Can you just remind us what is your typical range? What volumes do they assume?
Was that anything else beyond DRG? Anything on VBP? Because when we're doing the math, I think the exit rate is low singles
That seems slightly higher versus what we've heard from some of your peers so far. So maybe just talk about what is the updated gross margin assumption
can you just remind us what is pharma as a percentage of total company revenues and where is this exposure?
are you gaining any market share here within reagents? And how should we think of reagents growth in fiscal 2025
the guide of 2% to 5%, how did the segment outlooks compare relative to 3% to 5% and perhaps what drives the low-end versus the high-end?
sort of how are you looking at product versus channel play within soft tissue robotics
how are you thinking about margin cadence
What are you excited about when you look at '26? Feels like some of these super cycles were probably in second or third year. So what is incremental
you did bring up some destocking. So just talk about visibility on, you know, what gives us the constant destockings or any Salesforce disruption
comps did -- what was this just comping quarter sequentially or anything else that's going on within the knee performance?
questions around the CapEx environment. So maybe if you could just period by the broader CapEx environment in LIFEPAK 35 launch
Any comments on how LP 35 launch is going? I think in the past, you've commented about share gains. Curious on opportunity that you're seeing within Medical?
how should we think about progression? And I'm assuming tariff is mostly a back half impact in that $200 million, is this China versus Europe?
I know there was some noise around a DOJ investigation. If you could just clarify on how you got comfortable, that would be helpful
Inari, is the maximum dilution impact here 20 basis points, Glenn? Is that what you're saying? And Spine, I think the comment you made was Spine will be absorbed
what was underlying organic ex days? When you say back half is 6%, is that for core organic or pro forma organic inclusive BD
it looks like it was flattish, but for the period owned under Waters, it was up 5%
Q1 very pleased with double-digit growth. Your prior guidance I think, assume something like 4% to 5% to hit the midpoint of the guidance
Share count assumptions went up a tad versus prior guidance. Curious why no buyback assumptions within the guide
PFAS, GLP-1, are we still assuming 30 basis points of contribution? How are you thinking about China-India within that guidance framework
How are you incorporating some of the macro-related risks when you think about tariffs perhaps NIH spending cuts, perhaps potential cuts to agencies like EPA
you also made some interesting comments about you're seeing rapid increase in productivity in regions where you're seeing this transition
can you can you, give us a bridge from back half, right, when you did mid singles to 2% guidance at the midpoint for fiscal twenty six, how much of this is Salesforce reorg impact
You raised it by 50 basis points versus prior assumptions, right, but it's still down 100 basis points year-on-year. Can you give us a bridge